Lesional and non-lesional skin gene-expression profiles from Phase-3 clinical trials of Brodalumab

IL-17 antagonists induce impressive clinical benefit in psoriasis, but it is unknown too what extent cellular and molecular characteristics of psoriasis are suppressed by a clinically relevant dose and schedule of any IL-17 antagonist. Examine the effects the IL-17A receptor antagonist brodalumab, on the clinical and molecular characteristics of psoriasis, including IL-17 dependent gene-sets. A subset of 116 patients enrolled in three Phase-3 randomized clinical trials (AMAGINE-1,2,3) participated in a mechanistic sub-study where punch biopsies were collected for lesional and non-lesional skin between baseline and 12 weeks. The biopsy cohort included moderate-to-severe psoriasis patients treated with 140mg (n=46), 210mg (n=41) brodalumanb or placebo (n=29), 844 samples total. Affymetrix arrays were used to evaluate the treatment-induced changes in the expression profile of lesional skin.